Symbols / PACB
PACB Chart
About
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, the company provides Revio, Vega, Sequel, Sequel II, and Sequel IIe instruments which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. It serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. The company markets its products through a sales force and distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America, and South America. The company has a collaboration with DNAstack Inc. to provide federated dataset of HiFi whole genome sequencing data. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Medical Devices | Market Cap | 502.68M |
| Enterprise Value | 924.08M | Income | -546.38M | Sales | 160.00M |
| Book/sh | 0.02 | Cash/sh | 0.93 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | -4.07 | PEG | — |
| P/S | 3.14 | P/B | 92.50 | P/C | — |
| EV/EBITDA | -17.55 | EV/Sales | 5.78 | Quick Ratio | 5.79 |
| Current Ratio | 6.92 | Debt/Eq | 13131.84 | LT Debt/Eq | — |
| EPS (ttm) | -1.82 | EPS next Y | -0.41 | EPS Growth | — |
| Revenue Growth | 13.80% | Earnings | 2026-05-07 | ROA | -34.09% |
| ROE | -213.45% | ROIC | — | Gross Margin | 34.28% |
| Oper. Margin | -89.85% | Profit Margin | 0.00% | Shs Outstand | 301.91M |
| Shs Float | 296.16M | Short Float | 13.40% | Short Ratio | 4.21 |
| Short Interest | — | 52W High | 2.73 | 52W Low | 0.85 |
| Beta | 2.28 | Avg Volume | 7.77M | Volume | 2.58M |
| Target Price | $2.50 | Recom | Buy | Prev Close | $1.66 |
| Price | $1.67 | Change | 0.30% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$2.50
Mean price target
2. Current target
$1.67
Latest analyst target
3. DCF / Fair value
$2.50
Proxy: analyst mean price target (no FCF/EPS data available).
Ratings
Current target
$1.67
Low
$1.50
High
$3.00
Mean
$2.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-15 | main | Barclays | Equal-Weight → Equal-Weight | $2 |
| 2025-11-11 | main | Piper Sandler | Neutral → Neutral | $2 |
| 2025-11-10 | main | Stephens & Co. | Overweight → Overweight | $2 |
| 2025-08-11 | main | Piper Sandler | Neutral → Neutral | $2 |
| 2025-06-25 | main | Barclays | Equal-Weight → Equal-Weight | $2 |
| 2025-05-15 | main | Piper Sandler | Neutral → Neutral | $1 |
| 2025-05-15 | reit | Stephens & Co. | Overweight → Overweight | $2 |
| 2025-04-10 | main | Canaccord Genuity | Buy → Buy | $3 |
| 2025-03-25 | main | Scotiabank | Sector Outperform → Sector Outperform | $2 |
| 2025-02-20 | reit | Piper Sandler | Neutral → Neutral | $2 |
| 2025-02-18 | main | Goldman Sachs | Neutral → Neutral | $2 |
| 2025-02-18 | reit | Stephens & Co. | Overweight → Overweight | $3 |
| 2025-02-14 | reit | Stephens & Co. | Overweight → Overweight | $3 |
| 2025-01-23 | main | Goldman Sachs | Neutral → Neutral | $2 |
| 2024-11-11 | down | UBS | Buy → Neutral | $2 |
| 2024-11-11 | main | Scotiabank | Sector Outperform → Sector Outperform | $6 |
| 2024-11-11 | main | Piper Sandler | Neutral → Neutral | $3 |
| 2024-08-28 | main | Scotiabank | Sector Outperform → Sector Outperform | $7 |
| 2024-08-13 | main | Stephens & Co. | Overweight → Overweight | $3 |
| 2024-08-12 | main | Morgan Stanley | Equal-Weight → Equal-Weight | $2 |
- Why Is PacBio (PACB) Stock Soaring Today - Yahoo Finance ue, 24 Feb 2026 20
- Global genome network to speed answers for rare disease patients - Stock Titan ue, 24 Feb 2026 14
- Henry, CEO, sells PACB stock worth $752k - Investing.com Fri, 20 Feb 2026 01
- Insider Sale: See Remarks of $PACB Sells 14,952 Shares - Quiver Quantitative Fri, 20 Feb 2026 01
- Genomics Stocks That Deserve a Place in Your Portfolio in 2026 - Zacks Investment Research Fri, 20 Feb 2026 15
- Here's Why Pacific Biosciences of California (PACB) Fell More Than Broader Market - Nasdaq Fri, 30 Jan 2026 08
- PacBio: The Consumables Flywheel Is Turning. The Chart Wants Confirmation (NASDAQ:PACB) - Seeking Alpha Wed, 28 Jan 2026 08
- Pacific Biosciences of California (PACB) Stock Dips While Market Gains: Key Facts - Yahoo Finance Fri, 23 Jan 2026 08
- PACB Stock Down Despite Q3 Earnings Beat Estimates, Revenues Down Y/Y - Zacks Investment Research hu, 06 Nov 2025 08
- $PACB stock is up 13% today. Here's what we see in our data. - Quiver Quantitative Fri, 21 Nov 2025 08
- Why PacBio (PACB) Stock Is Up Today - Yahoo Finance Wed, 03 Dec 2025 08
- Why Is PacBio (PACB) Stock Soaring Today - Yahoo Finance Wed, 31 Dec 2025 08
- PACB Stock Down Despite Q3 Earnings Beat Estimates, Revenues Down Y/Y - Yahoo Finance hu, 06 Nov 2025 08
- PacBio (PACB) Stock Is Up, What You Need To Know - Yahoo Finance Fri, 24 Oct 2025 07
- PacBio (PACB): Buy, Sell, or Hold Post Q4 Earnings? - Yahoo! Finance Canada Fri, 20 Feb 2026 04
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 184897 | 294318 | — | Sale at price 1.58 - 1.63 per share. | VAN OENE MARK D | Chief Operating Officer | — | 2026-02-18 00:00:00 | D |
| 1 | 50167 | 79856 | — | Sale at price 1.58 - 1.63 per share. | FARMER MICHELE CPA | Officer | — | 2026-02-18 00:00:00 | D |
| 2 | 472667 | 752390 | — | Sale at price 1.58 - 1.63 per share. | HENRY CHRISTIAN O | Chief Executive Officer | — | 2026-02-18 00:00:00 | D |
| 3 | 26836 | 35182 | — | Sale at price 1.31 per share. | VAN OENE MARK D | Chief Operating Officer | — | 2025-08-18 00:00:00 | D |
| 4 | 5195 | 5200 | — | Sale at price 1.00 per share. | FARMER MICHELE CPA | Officer | — | 2025-05-19 00:00:00 | D |
| 5 | 1000000 | — | — | Stock Award(Grant) at price 0.00 per share. | GIBSON JAMES R II | Chief Financial Officer | — | 2025-03-31 00:00:00 | D |
| 6 | 920810 | — | — | Stock Award(Grant) at price 0.00 per share. | HENRY CHRISTIAN O | Chief Executive Officer | — | 2025-03-19 00:00:00 | D |
| 7 | 449176 | — | — | Stock Award(Grant) at price 0.00 per share. | VAN OENE MARK D | Chief Operating Officer | — | 2025-03-19 00:00:00 | D |
| 8 | 89835 | — | — | Stock Award(Grant) at price 0.00 per share. | FARMER MICHELE CPA | Officer | — | 2025-03-19 00:00:00 | D |
| 9 | 6486 | 9126 | — | Sale at price 1.41 per share. | VAN OENE MARK D | Officer | — | 2025-03-03 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -6.14M | -940.86K | -2.38K | -28.65M |
| TaxRateForCalcs | 0.21 | 0.04 | 0.00 | 0.34 |
| NormalizedEBITDA | -213.53M | -251.15M | -279.86M | -166.49M |
| TotalUnusualItems | -29.24M | -26.14M | -2.38M | -84.27M |
| TotalUnusualItemsExcludingGoodwill | -29.24M | -26.14M | -2.38M | -84.27M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -309.85M | -306.74M | -314.25M | -181.22M |
| ReconciledDepreciation | 53.35M | 26.53M | 17.32M | 11.59M |
| ReconciledCostOfRevenue | 81.39M | 127.36M | 61.95M | 60.07M |
| EBITDA | -242.77M | -277.28M | -282.24M | -250.76M |
| EBIT | -296.12M | -303.82M | -299.56M | -262.34M |
| NetInterestIncome | -13.41M | -14.34M | -14.69M | -12.53M |
| InterestExpense | 13.41M | 14.34M | 14.69M | 12.53M |
| NormalizedIncome | -286.75M | -281.54M | -311.87M | -125.60M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -309.85M | -306.74M | -314.25M | -181.22M |
| TotalExpenses | 444.68M | 510.89M | 433.12M | 308.68M |
| TotalOperatingIncomeAsReported | -474.31M | -334.47M | -307.20M | -210.44M |
| DilutedAverageShares | 288.37M | 253.63M | 224.55M | 204.14M |
| BasicAverageShares | 274.49M | 253.63M | 224.55M | 204.14M |
| DilutedEPS | -1.58 | -1.21 | -1.40 | -0.89 |
| BasicEPS | -1.12 | -1.21 | -1.40 | -0.89 |
| DilutedNIAvailtoComStockholders | -309.85M | -306.74M | -314.25M | -181.22M |
| NetIncomeCommonStockholders | -309.85M | -306.74M | -314.25M | -181.22M |
| NetIncome | -309.85M | -306.74M | -314.25M | -181.22M |
| NetIncomeIncludingNoncontrollingInterests | -309.85M | -306.74M | -314.25M | -181.22M |
| NetIncomeContinuousOperations | -309.85M | -306.74M | -314.25M | -181.22M |
| TaxProvision | 316.00K | -11.42M | 0.00 | -93.65M |
| PretaxIncome | -309.54M | -318.16M | -314.25M | -274.87M |
| OtherIncomeExpense | -5.46M | 6.55M | 5.26M | -84.18M |
| OtherNonOperatingIncomeExpenses | 23.78M | 32.68M | 7.64M | 93.00K |
| SpecialIncomeCharges | -29.24M | -26.14M | -2.38M | -84.27M |
| OtherSpecialCharges | -154.41M | 2.03M | 52.00M | |
| WriteOff | 184.50M | 0.00 | 0.00 | |
| RestructuringAndMergernAcquisition | -850.00K | 24.10M | 2.38M | 32.27M |
| NetNonOperatingInterestIncomeExpense | -13.41M | -14.34M | -14.69M | -12.53M |
| InterestExpenseNonOperating | 13.41M | 14.34M | 14.69M | 12.53M |
| OperatingIncome | -290.66M | -310.37M | -304.82M | -178.16M |
| OperatingExpense | 327.94M | 363.14M | 353.85M | 237.02M |
| DepreciationAmortizationDepletionIncomeStatement | 18.01M | 6.16M | 0.00 | 0.00 |
| DepreciationAndAmortizationInIncomeStatement | 18.01M | 6.16M | 0.00 | 0.00 |
| Amortization | 18.01M | 6.16M | 0.00 | 0.00 |
| AmortizationOfIntangiblesIncomeStatement | 18.01M | 6.16M | 0.00 | 0.00 |
| ResearchAndDevelopment | 134.92M | 187.17M | 193.00M | 112.90M |
| SellingGeneralAndAdministration | 175.02M | 169.82M | 160.85M | 124.12M |
| GrossProfit | 37.28M | 52.78M | 49.03M | 58.86M |
| CostOfRevenue | 116.73M | 147.74M | 79.27M | 71.65M |
| TotalRevenue | 154.01M | 200.52M | 128.30M | 130.51M |
| OperatingRevenue | 154.01M | 200.52M | 128.30M | 130.51M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 294.42M | 267.74M | 226.50M | 220.98M |
| ShareIssued | 294.42M | 267.74M | 226.50M | 220.98M |
| NetDebt | 592.12M | 712.82M | 573.44M | 436.95M |
| TotalDebt | 672.43M | 933.93M | 948.48M | 955.36M |
| TangibleBookValue | -200.74M | -217.94M | -257.31M | -29.97M |
| InvestedCapital | 1.15B | 1.59B | 1.46B | 1.69B |
| WorkingCapital | 429.38M | 647.02M | 588.74M | 1.03B |
| NetTangibleAssets | -200.74M | -217.94M | -257.31M | -29.97M |
| CapitalLeaseObligations | 24.94M | 41.20M | 49.96M | 57.68M |
| CommonStockEquity | 506.59M | 701.30M | 562.90M | 790.99M |
| TotalCapitalization | 1.15B | 1.59B | 1.46B | 1.69B |
| TotalEquityGrossMinorityInterest | 506.59M | 701.30M | 562.90M | 790.99M |
| StockholdersEquity | 506.59M | 701.30M | 562.90M | 790.99M |
| GainsLossesNotAffectingRetainedEarnings | 422.00K | 219.00K | -4.76M | -1.09M |
| OtherEquityAdjustments | 422.00K | 219.00K | -4.76M | -1.09M |
| RetainedEarnings | -2.15B | -1.84B | -1.53B | -1.22B |
| AdditionalPaidInCapital | 2.65B | 2.54B | 2.10B | 2.01B |
| CapitalStock | 294.00K | 268.00K | 227.00K | 221.00K |
| CommonStock | 294.00K | 268.00K | 227.00K | 221.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 753.85M | 1.04B | 1.20B | 1.22B |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 687.55M | 949.68M | 940.85M | 1.14B |
| OtherNonCurrentLiabilities | 19.25M | 20.30M | 1.30M | 173.19M |
| NonCurrentDeferredLiabilities | 5.90M | 5.53M | 1.79M | 25.05M |
| NonCurrentDeferredRevenue | 5.90M | 5.53M | 1.79M | 25.05M |
| LongTermDebtAndCapitalLeaseObligation | 662.41M | 923.85M | 937.75M | 946.04M |
| LongTermCapitalLeaseObligation | 14.91M | 31.61M | 41.07M | 49.97M |
| LongTermDebt | 647.49M | 892.24M | 896.68M | 896.07M |
| CurrentLiabilities | 66.30M | 95.03M | 263.33M | 71.71M |
| OtherCurrentLiabilities | 1.21M | 4.12M | 173.85M | 553.00K |
| CurrentDeferredLiabilities | 13.86M | 16.34M | 30.50M | 10.98M |
| CurrentDeferredRevenue | 13.86M | 16.34M | 30.50M | 10.98M |
| CurrentDebtAndCapitalLeaseObligation | 10.03M | 10.08M | 10.73M | 9.32M |
| CurrentCapitalLeaseObligation | 10.03M | 9.59M | 8.89M | 7.71M |
| CurrentDebt | 490.00K | 1.84M | 1.61M | |
| OtherCurrentBorrowings | 490.00K | 1.84M | 1.61M | |
| PensionandOtherPostRetirementBenefitPlansCurrent | 2.01M | 3.71M | 3.64M | 3.60M |
| PayablesAndAccruedExpenses | 39.19M | 60.77M | 44.62M | 47.26M |
| CurrentAccruedExpenses | 22.59M | 45.71M | 32.60M | 36.26M |
| InterestPayable | 2.47M | 2.83M | 5.10M | 5.10M |
| Payables | 16.59M | 15.06M | 12.03M | 11.00M |
| AccountsPayable | 16.59M | 15.06M | 12.03M | 11.00M |
| TotalAssets | 1.26B | 1.75B | 1.77B | 2.01B |
| TotalNonCurrentAssets | 764.77M | 1.00B | 915.01M | 905.84M |
| OtherNonCurrentAssets | 10.84M | 15.70M | 13.45M | 5.76M |
| GoodwillAndOtherIntangibleAssets | 707.33M | 919.25M | 820.22M | 820.95M |
| OtherIntangibleAssets | 389.57M | 456.98M | 410.25M | 410.98M |
| Goodwill | 317.76M | 462.26M | 409.97M | 409.97M |
| NetPPE | 46.60M | 69.03M | 81.34M | 79.12M |
| AccumulatedDepreciation | -81.95M | -74.79M | -64.99M | -56.29M |
| GrossPPE | 128.54M | 143.82M | 146.33M | 135.41M |
| Leases | 33.77M | 35.23M | 34.13M | 31.11M |
| ConstructionInProgress | 2.28M | 1.34M | 4.70M | 2.30M |
| OtherProperties | 16.09M | 32.59M | 39.76M | 46.62M |
| MachineryFurnitureEquipment | 76.41M | 74.66M | 67.74M | 55.37M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 495.68M | 742.05M | 852.07M | 1.10B |
| OtherCurrentAssets | 18.78M | 17.04M | 10.29M | 7.39M |
| RestrictedCash | 690.00K | 300.00K | 300.00K | 500.00K |
| PrepaidAssets | 10.29M | 7.39M | ||
| Inventory | 58.76M | 56.68M | 50.38M | 24.60M |
| InventoriesAdjustmentsAllowances | -22.77M | -19.16M | ||
| FinishedGoods | 14.08M | 15.75M | 12.18M | 8.00M |
| WorkInProcess | 22.17M | 27.65M | 14.06M | 8.61M |
| RawMaterials | 45.27M | 32.43M | 24.14M | 7.99M |
| Receivables | 27.52M | 36.62M | 18.79M | 24.24M |
| AccountsReceivable | 27.52M | 36.62M | 18.79M | 24.24M |
| CashCashEquivalentsAndShortTermInvestments | 389.93M | 631.42M | 772.32M | 1.04B |
| OtherShortTermInvestments | 334.56M | 451.50M | 447.23M | 583.67M |
| CashAndCashEquivalents | 55.37M | 179.91M | 325.09M | 460.73M |
| CashEquivalents | 0.00 | 109.74M | 187.45M | 133.41M |
| CashFinancial | 55.37M | 70.17M | 137.64M | 327.31M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -212.25M | -268.02M | -280.14M | -117.11M |
| RepaymentOfDebt | -490.00K | -1.84M | -1.61M | -361.00K |
| IssuanceOfDebt | 0.00 | 0.00 | 895.54M | |
| IssuanceOfCapitalStock | 0.00 | 189.20M | 0.00 | 294.85M |
| CapitalExpenditure | -6.19M | -8.84M | -16.93M | -5.93M |
| InterestPaidSupplementalData | 14.80M | 15.69M | 14.05M | 6.93M |
| EndCashPosition | 55.37M | 179.91M | 325.09M | 460.73M |
| OtherCashAdjustmentOutsideChangeinCash | -2.22M | -2.72M | -3.22M | -5.09M |
| BeginningCashPosition | 182.63M | 328.31M | 465.82M | 85.95M |
| ChangesInCash | -125.04M | -145.68M | -137.51M | 379.87M |
| FinancingCashFlow | -42.99M | 108.89M | 9.62M | 1.17B |
| CashFlowFromContinuingFinancingActivities | -42.99M | 108.89M | 9.62M | 1.17B |
| NetOtherFinancingCharges | -50.20M | -93.79M | -52.24M | |
| ProceedsFromStockOptionExercised | 7.70M | 15.32M | 11.23M | 31.81M |
| NetCommonStockIssuance | 0.00 | 189.20M | 0.00 | 294.85M |
| CommonStockIssuance | 0.00 | 189.20M | 0.00 | 294.85M |
| NetIssuancePaymentsOfDebt | -490.00K | -1.84M | -1.61M | 895.17M |
| NetLongTermDebtIssuance | -490.00K | -1.84M | -1.61M | 895.17M |
| LongTermDebtPayments | -490.00K | -1.84M | -1.61M | -361.00K |
| LongTermDebtIssuance | 0.00 | 0.00 | 895.54M | |
| InvestingCashFlow | 124.00M | 4.60M | 116.08M | -678.53M |
| CashFlowFromContinuingInvestingActivities | 124.00M | 4.60M | 116.08M | -678.53M |
| NetInvestmentPurchaseAndSale | 130.19M | 13.55M | 133.01M | -352.81M |
| SaleOfInvestment | 628.83M | 770.12M | 575.80M | 635.24M |
| PurchaseOfInvestment | -498.63M | -756.57M | -442.79M | -988.05M |
| NetBusinessPurchaseAndSale | 0.00 | -102.00K | 0.00 | -319.79M |
| PurchaseOfBusiness | 0.00 | -102.00K | 0.00 | -319.79M |
| NetIntangiblesPurchaseAndSale | 0.00 | 0.00 | -179.00K | 0.00 |
| PurchaseOfIntangibles | 0.00 | 0.00 | -179.00K | 0.00 |
| NetPPEPurchaseAndSale | -6.19M | -8.84M | -16.75M | -5.93M |
| PurchaseOfPPE | -6.19M | -8.84M | -16.75M | -5.93M |
| OperatingCashFlow | -206.06M | -259.17M | -263.21M | -111.18M |
| CashFlowFromContinuingOperatingActivities | -206.06M | -259.17M | -263.21M | -111.18M |
| ChangeInWorkingCapital | -40.58M | -58.96M | -53.97M | 20.33M |
| ChangeInOtherWorkingCapital | -2.11M | -10.42M | -3.73M | 25.74M |
| ChangeInOtherCurrentLiabilities | -16.53M | -21.19M | -6.84M | -5.79M |
| ChangeInPayablesAndAccruedExpense | -24.94M | 13.31M | -2.63M | 21.68M |
| ChangeInAccruedExpense | -26.34M | 13.10M | -3.65M | 15.32M |
| ChangeInPayable | 1.41M | 206.00K | 1.02M | 6.36M |
| ChangeInAccountPayable | 1.41M | 206.00K | 1.02M | 6.36M |
| ChangeInPrepaidAssets | 2.23M | -8.98M | -12.32M | -1.02M |
| ChangeInInventory | -8.32M | -13.84M | -33.91M | -13.11M |
| ChangeInReceivables | 9.09M | -17.83M | 5.46M | -7.17M |
| ChangesInAccountReceivables | 9.09M | -17.83M | 5.46M | -7.17M |
| OtherNonCashItems | -155.88M | 19.51M | 3.29M | 53.74M |
| StockBasedCompensation | 71.04M | 72.12M | 78.61M | 73.36M |
| ProvisionandWriteOffofAssets | 4.62M | 10.58M | 6.03M | 678.00K |
| AssetImpairmentCharge | 184.50M | 0.00 | 0.00 | |
| AmortizationOfSecurities | -13.04M | -12.84M | -244.00K | 4.01M |
| DeferredTax | -205.00K | -11.42M | 0.00 | -93.65M |
| DeferredIncomeTax | -205.00K | -11.42M | 0.00 | -93.65M |
| DepreciationAmortizationDepletion | 53.35M | 26.53M | 17.32M | 11.59M |
| DepreciationAndAmortization | 53.35M | 26.53M | 17.32M | 11.59M |
| AmortizationCashFlow | 27.41M | 8.26M | 913.00K | 381.00K |
| AmortizationOfIntangibles | 27.41M | 8.26M | 913.00K | 381.00K |
| Depreciation | 25.94M | 18.27M | 16.41M | 11.20M |
| OperatingGainsLosses | 2.03M | 278.00K | 54.00K | |
| GainLossOnSaleOfPPE | 278.00K | 54.00K | ||
| NetIncomeFromContinuingOperations | -309.85M | -306.74M | -314.25M | -181.22M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for PACB
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|